The Center for Drug Evaluation and Research (CDER) has established a formal working agreement with the Office of the Chief Scientist, aimed at enhancing the regulatory framework surrounding cosmetic products. This collaboration is designed to streamline processes and improve compliance mechanisms, reflecting a growing recognition of the need for robust oversight in the cosmetic sector.
This agreement comes at a time when the cosmetic industry faces increasing scrutiny over product safety and efficacy. By aligning the expertise of CDER with the scientific oversight from the Chief Scientist’s office, the FDA is positioning itself to better address emerging challenges in cosmetic regulation, including the rise of new ingredients and formulations that may pose safety concerns.
The implications of this agreement are significant for pharma B2B professionals across regulatory, QA/QC, and sourcing sectors. Enhanced collaboration between these divisions may lead to more consistent regulatory interpretations and a more unified approach to compliance, ultimately benefiting industry stakeholders and consumers alike.
Start your 7-day trial and see what the database can do →
